Crape Jasmine — Benefits Deep Dive

Crape jasmine’s fame rests on a single molecule its own tissue barely makes. Conolidine, the non-opioid analgesic story that put Tabernaemontana divaricata into pharmacology journals, occurs in such trace quantity in the bark that the compound had to be chemically synthesised before anyone could test what it does — the plant itself could never have supplied enough. That is the fact this Benefits leg has to hold onto throughout: the most exciting thing ever said about this shrub is a discovery about a synthesised molecule, not a demonstrated property of the plant a person could actually consume. What follows asks a narrower, more answerable question instead — does the whole plant extract, the thing a traditional healer or a curious gardener might actually prepare, do anything measurable? — and the honest answer is more interesting than either “yes, it is a wonder herb” or “no, there is nothing here.”

There is a genuine, if entirely preclinical, body of work on crape jasmine’s whole-plant extracts: rat and mouse studies of wound healing, anti-inflammatory activity, antinociception, gastroprotection, and — the deepest and most reproducible strand — inhibition of acetylcholinesterase, the enzyme real Alzheimer’s drugs also target. Several independent Thai research groups have returned to this plant across two decades for exactly that last property. None of this has ever been tested in a person. None of it comes with a dose. And several of the alkaloids doing the work in these studies are chemically one or two steps from ibogaine, a substance with a documented history of fatal cardiac arrhythmia. The same chemistry that makes this plant pharmacologically interesting is the chemistry the main topic page uses to justify giving no dose at all.

These four articles take the plant’s claimed benefits seriously enough to check them against the primary literature rather than against what a search engine returns. That means separating what conolidine — the drug candidate — can claim from what crape jasmine extract — the plant — can claim, two different evidence bases that get run together constantly. It means naming exactly which alkaloids are documented in this species rather than borrowed from a related genus, because the surrounding literature makes that easy to get wrong in both directions. It means reading a green-synthesis nanoparticle paper for what it actually tested (an inorganic nanomaterial, not the herb) rather than what a supplement label might imply it proved. And it means stating, in every section, that the single most important fact about every claim below is that none of it has reached a human trial.

Deep-Dive Articles

Wound Healing, Skin, and Antimicrobial Claims

The traditional external-use record — root paste, latex, leaf poultice — set against real rat wound-healing and anti-inflammatory data, a genuinely interesting latex protease family that cuts both ways, and why a plant used to make antibacterial nanoparticles is not the same as a plant shown to be antibacterial.

Analgesic and Anti-Inflammatory Claims: Conolidine and Beyond

The Nature Chemistry conolidine story, properly separated from a second, less famous dataset: what the whole flower and leaf extract actually does to pain and inflammation in rodents, through mechanisms that turn out to be — inconveniently for the “non-opioid” headline — partly classical opioid signalling.

Cognitive and Neuroprotective Claims: Acetylcholinesterase Inhibition

The plant’s deepest and most reproducible evidence base: two decades of Thai laboratory work isolating specific alkaloids that inhibit the same enzyme donepezil and galantamine target, capped by what those approved drugs already show about the ceiling on this mechanism.

Alkaloid Pharmacology and the Real Toxicity Profile

Sixty-six named alkaloids, real cytotoxic and antidiabetic activity from specific isolated compounds, and the precise chemistry — not vague family-level fear — behind why several of them sit one synthetic step from a drug with a documented history of fatal arrhythmia.

Back to Table of Contents

Table of Contents

  1. Deep-Dive Articles
  2. Evidence Ledger
  3. The Trace-Compound Problem
  4. Where the Marketing Runs Ahead of the Paper
  5. Key Research: Wound Healing, Skin and Antimicrobial
  6. Key Research: Analgesic and Anti-Inflammatory
  7. Key Research: Cognitive and Neuroprotective
  8. Key Research: Alkaloid Chemistry and Toxicity
  9. External Resources
  10. Connections

Evidence Ledger

Ranked by the strength of the evidence itself, not by how often a claim gets repeated online — which is the opposite order a search result would give you.

  1. Acetylcholinesterase inhibition, whole extract and isolated alkaloids. Tier: preclinical, reproduced independently across at least four Thai research groups over roughly twenty years — in-vitro enzyme assays, an ex-vivo hippocampal slice preparation, in-vivo rat cortex, and one amyloid-β mouse model. The deepest and most consistent evidence base on this plant. Zero human data of any kind.
  2. Conolidine as a non-opioid analgesic drug lead. Tier: a single, rigorous, high-profile synthesis-and-pharmacology finding, independently confirmed mechanistically a decade later. Real science — about a synthesised molecule the plant cannot supply in usable quantity, not about the plant.
  3. Whole-extract antinociceptive and anti-inflammatory activity. Tier: preclinical, several independent rodent studies with real dose-response data, through mixed mechanisms — some naloxone-reversible and classically opioid, some not. Never tested in a person.
  4. Wound healing in excision, incision and burn models. Tier: preclinical, one recent (2024) but methodologically solid rat study across three wound-model types, unreplicated by any other laboratory.
  5. Cytotoxicity toward cancer cell lines in vitro. Tier: preclinical, several independent groups, genuine sub-micromolar potency for specific alkaloids — and simultaneously a toxicity signal rather than a therapeutic one, since most of this work did not test selectivity against normal tissue.
  6. Hepatoprotective activity in a rat carcinogen-exposure model. Tier: single study, positive, unreplicated. Worth stating plainly because it runs against this plant’s generally cautionary profile — a herb this alkaloid-rich is not automatically hepatotoxic, and here the one dedicated liver study found the opposite of harm.
  7. Antidiabetic activity of conophylline. Tier: preclinical, real oral efficacy across two rat models — but the compound was first characterised in a different, related species and occurs in only modest amount even in T. divaricata material.
  8. Antimicrobial and antifungal claims. Tier: mixed and mostly indirect — one green-synthesis nanoparticle study (evidence about a nanomaterial, not the herb), one synergist-only finding against drug-resistant Candida, one small dental-pathogen study, and one purely computational docking exercise never tested against a living organism.
  9. Traditional eye and ophthalmic use. Tier: historical ethnobotanical record only. Zero pharmacological testing exists. The main topic page already states plainly that this specific traditional use is now understood to be actively hazardous, and nothing in the literature searched for this leg changes that.
  10. Human efficacy or safety data for the whole plant, in any preparation, for any indication. Tier: absent. This is true of every row above it, and it is the fact that governs how all of them should be read.

The Trace-Compound Problem

Start with what actually happened. Conolidine is an unusual alkaloid found in only trace amounts in T. divaricata bark — so little that nobody could isolate enough of it from the plant to run a pharmacology experiment. In 2011, a chemistry group led by Glenn Micalizio solved that problem by synthesising conolidine from scratch, and Laura Bohn’s pharmacology group then tested the synthetic compound in rodent pain models, where it produced meaningful analgesia without acting through the classical mu, delta or kappa opioid receptors. A decade later, a separate group identified the likely target: ACKR3/CXCR7, an atypical chemokine receptor that behaves like a scavenger for the body’s own opioid peptides, so that blocking it may raise local levels of natural enkephalins and endorphins rather than flooding opioid receptors with an external drug. That mechanism paper appeared in Signal Transduction and Targeted Therapy in 2021, and a clinical-facing review the same year framed conolidine as a candidate for chronic non-cancer pain management amid the opioid crisis. All of this is genuine, citable, interesting science.

None of it is evidence about the plant. The research exists because there was too little conolidine in T. divaricata to study directly — a root or bark decoction cannot deliver a pharmacological dose of a compound that had to be built in a lab to get enough of it. Anyone who reads “crape jasmine contains a powerful new non-opioid painkiller” and concludes that a preparation of the plant will relieve pain the way the synthesised molecule did in mice is making an error the doctrine on this site exists to catch: crediting a whole plant with a property that belongs to one trace, unsynthesisable-in-situ constituent.

But that is not the end of the analgesia story, and collapsing it to “the plant has no real pain-relief evidence” would be its own error. A completely separate line of work has tested the whole flower extract — not purified conolidine — in standard rodent pain assays, and found real, dose-dependent antinociceptive activity, attributable to three different, better-characterised alkaloids the researchers actually isolated: voacangine, catharanthine, and O-acetyl vallesamine. Part of that effect was blocked by naloxone, meaning it works, at least in part, through the same classical opioid receptors morphine acts on — the opposite of conolidine’s selling point. So the accurate picture has two separate, non-overlapping stories layered under one plant name: a synthesised trace molecule with a genuinely novel non-opioid mechanism and no route from plant to patient, and a whole-extract effect that is real in rodents, attributable to different named alkaloids, delivered at an unknown and unstandardised dose, and partly running through the same opioid pathway that makes an uncontrolled dose of any opioid-active material a real hazard rather than a curiosity. Neither of those two stories licenses drinking a preparation of this plant for pain. See the Analgesic and Anti-Inflammatory Claims page for the full account, including the gastroprotective and anti-inflammatory extract data that sits alongside it.

One more precision point worth flagging here because it recurs throughout this leg: catharanthine, one of the three alkaloids isolated from crape jasmine’s flowers in that antinociception study, is also the signature alkaloid of Catharanthus roseus — Madagascar periwinkle, the source plant for the chemotherapy drugs vincristine and vinblastine. Finding the same compound in a second Apocynaceae genus is a real and unsurprising chemotaxonomic fact, since related plant families frequently share biosynthetic machinery. It is not evidence that crape jasmine is, or could become, a chemotherapy source; industrial vincristine production still runs through periwinkle, not this shrub.

Where the Marketing Runs Ahead of the Paper

Six specific ways this plant’s literature gets overstated, each labelled again at the point it appears in the four sub-articles rather than only here, because a reader who arrives on one page directly should not have to have read this one first.

  1. Nanoparticle substitution. A widely circulated study reporting antibacterial activity from crape jasmine leaf extract actually used the extract as a reducing and capping agent to synthesise zinc oxide nanoparticles, then tested the resulting nanomaterial against bacteria. Zinc oxide nanoparticles are broadly antibacterial regardless of which plant reduced the zinc salt during synthesis. “Crape jasmine makes antibacterial nanoparticles when used in a materials-science process” is what was shown; “crape jasmine is antibacterial” is not.
  2. Synergist-only substitution. A 2021 phytochemistry paper isolated eleven new alkaloids from this plant and found that several of them restored fluconazole’s effectiveness against drug-resistant Candida albicans — but explicitly, none of the alkaloids showed any activity against the resistant strain alone. That is a real and useful finding about overcoming antifungal resistance in combination with an existing drug. It is not a standalone antifungal claim.
  3. Species-of-origin precision. Conophylline, one of this plant’s more pharmacologically active alkaloids, is described in its own foundational literature as a compound of Ervatamia microphylla, a related but different species. It has since been independently isolated and structurally confirmed from T. divaricata itself, so citing conophylline research for crape jasmine is legitimate — but only once the source material in a given study is checked, and the compound should not be assumed to belong exclusively, or even primarily, to this species.
  4. Compound-versus-species substitution in the safety literature. The cardiac-arrhythmia and hERG-channel-blockade research behind this plant’s most serious safety caution is about ibogaine itself, and about voacangine extracted from other Tabernaemontana and Voacanga species used in the ibogaine trade. It establishes a class-level, mechanism-level rationale for caution around T. divaricata’s own voacangine content. It is not a direct report of this species poisoning a person.
  5. Marker compound is not an identity check. Voacangine and coronaridine are shared iboga-type alkaloids across multiple genera — Tabernaemontana, Voacanga, Tabernanthe. A product “standardised” to either compound cannot, on that basis alone, be confirmed as made from this species rather than a botanical relative.
  6. Computational-only evidence. One antibacterial “finding” in this literature is a molecular-docking exercise run entirely in software, predicting which crape jasmine compounds might bind bacterial proteins. Nothing in that paper was tested against a living bacterium.

Back to Table of Contents

Key Research: Wound Healing, Skin and Antimicrobial

Every citation on this hub and across all four sub-articles is a PubMed search built from author names and distinctive title words and confirmed live before publication, so a link cannot silently resolve to the wrong paper or the wrong species — a real risk in this genus, where Ervatamia and Tabernaemontana names for the same plant, and several related but distinct species, share the indexed literature.

  1. Gargate N, Raut S, Kapare H, Shende P, Bhole R. Formulation, characterization and in-vivo evaluation of standardized Tabernaemontana divaricata extract hydrogel for wound healing. Journal of Ayurveda and Integrative Medicine, 2024. Excision, incision and burn wound models in rats; the strongest single dataset for this claim. Find on PubMed.
  2. Singh MK, Rajagopalan A, Tanimu H, Sukumaran BO. Purification, characterization and fibrino(geno)lytic activity of cysteine protease from Tabernaemontana divaricata latex. 3 Biotech, 2021. The enzyme mechanism behind both the wound claim and the irritancy caution. Find on PubMed.
  3. Jain S, Sharma P, Ghule S, Jain A, Jain N. In vivo anti-inflammatory activity of Tabernaemontana divaricata leaf extract on male albino mice. Chinese Journal of Natural Medicines, 2013. Topical croton-oil ear-oedema model, matching the traditional route of use. Find on PubMed.
  4. Henriques AT, Melo AA, Moreno PR, Ene LL, Henriques JA, Schapoval EE. Ervatamia coronaria: chemical constituents and some pharmacological activities. Journal of Ethnopharmacology, 1996. Anti-inflammatory and analgesic activity in rats, plus isolation of coronaridine, heyneanine, voacristine and voacamine. Find on PubMed.
  5. Raja A, Ashokkumar S, Pavithra Marthandam R, et al. Eco-friendly preparation of zinc oxide nanoparticles using Tabernaemontana divaricata and its photocatalytic and antimicrobial activity. Journal of Photochemistry and Photobiology B, 2018. Read as nanomaterial science, not herbal antimicrobial evidence — see the overstatement section above. Find on PubMed.
  6. John MK, Cheriyan DZ. Anticariogenic potential of Tabernaemontana divaricata. Indian Journal of Dental Research, 2023. Leaf extract against S. mutans and L. acidophilus, the common cavity-causing bacteria. Find on PubMed.
  7. Zhang Y, Bai X, Yuwen HS, Guo LL, Liu JW, Hao XJ. Alkaloids from Tabernaemontana divaricata combined with fluconazole to overcome fluconazole resistance in Candida albicans. Bioorganic Chemistry, 2021. Synergist only — none of the alkaloids worked alone. Find on PubMed.
  8. Gogoi RR, Gogoi D, Bezbaruah RL. Virtual screening of compounds from Tabernaemontana divaricata for potential anti-bacterial activity. Bioinformation, 2014. Computational docking only — never tested against a live organism. Find on PubMed.
  9. Bhadane BS, Patil MP, Maheshwari VL, Patil RH. Ethnopharmacology, phytochemistry, and biotechnological advances of family Apocynaceae: a review. Phytotherapy Research, 2018. Names T. divaricata among the family’s most extensively studied plants. Find on PubMed.

Back to Table of Contents

Key Research: Analgesic and Anti-Inflammatory

  1. Tarselli MA, Raehal KM, Brasher AK, Streicher JM, Groer CE, Cameron MD, Bohn LM, Micalizio GC. Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain. Nature Chemistry, 2011. The foundational finding — about a synthesised molecule. Find on PubMed.
  2. Szpakowska M, Decker AM, Meyrath M, et al. The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7. Signal Transduction and Targeted Therapy, 2021. The mechanism, a decade after the original synthesis. Find on PubMed.
  3. Edinoff AN, Patel AS, Baker MW, et al. Conolidine: a novel plant extract for chronic pain. Anesthesiology and Pain Medicine, 2021. A clinical-facing review situating conolidine amid the opioid-prescribing crisis. Find on PubMed.
  4. Ali Khan MS, Misbah, Ahmed N, Arifuddin M, Rehman A, Ling MP. Indole alkaloids and anti-nociceptive mechanisms of Tabernaemontana divaricata flower methanolic extract. Food and Chemical Toxicology, 2018. The separate whole-extract dataset — partly naloxone-reversible. Find on PubMed.
  5. Ali Khan MS, Mat Jais AM, Afreen A. Prostaglandin analogous and antioxidant activity mediated gastroprotective action of Tabernaemontana divaricata flower methanolic extract against chemically induced gastric ulcers in rats. BioMed Research International, 2013. Real dose-response gastroprotection, versus misoprostol as a positive control. Find on PubMed.
  6. Khan MA, Islam MT. Analgesic and cytotoxic activity of Acorus calamus L., Kigelia pinnata L., Mangifera indica L. and Tabernaemontana divaricata L. Journal of Pharmacy & Bioallied Sciences, 2012. Reports per-species numbers; crape jasmine’s writhing-protection was the weakest of the four plants tested. Find on PubMed.
  7. Pratchayasakul W, Pongchaidecha A, Chattipakorn N, Chattipakorn S. Ethnobotany & ethnopharmacology of Tabernaemontana divaricata. Indian Journal of Medical Research, 2008. The standard review; lists analgesia among the genus’s documented preclinical properties. Find on PubMed.

Back to Table of Contents

Key Research: Cognitive and Neuroprotective

  1. Ingkaninan K, De Best R, van der Heijden R, et al. Screening for acetylcholinesterase inhibitory activity in plants used in Thai traditional rejuvenating and neurotonic remedies. Journal of Ethnopharmacology, 2003. The screening study that opened this whole line of research. Find on PubMed.
  2. Ingkaninan K, Changwijit K, Suwanborirux K. Vobasinyl-iboga bisindole alkaloids, potent acetylcholinesterase inhibitors from Tabernaemontana divaricata root. Journal of Pharmacy and Pharmacology, 2006. Two named alkaloids outperforming galanthamine in vitro. Find on PubMed.
  3. Chattipakorn S, Pongpanparadorn A, Pratchayasakul W, Pongchaidacha A, Ingkaninan K, Chattipakorn N. Tabernaemontana divaricata extract inhibits neuronal acetylcholinesterase activity in rats. Journal of Ethnopharmacology, 2007. The first in-vivo confirmation. Find on PubMed.
  4. Pratchayasakul W, Pongchaidecha A, Chattipakorn N, Chattipakorn SC. Reversible acetylcholinesterase inhibitory effect of Tabernaemontana divaricata extract on synaptic transmission in rat CA1 hippocampus. Indian Journal of Medical Research, 2010. Electrophysiology, compared directly with galanthamine. Find on PubMed.
  5. Chaiyana W, Schripsema J, Ingkaninan K, Okonogi S. 3′-R/S-hydroxyvoacamine, a potent acetylcholinesterase inhibitor from Tabernaemontana divaricata. Phytomedicine, 2013. A specific, quantified IC50 value for a named stem alkaloid. Find on PubMed.
  6. Chaiyana W, Rades T, Okonogi S. Characterization and in vitro permeation study of microemulsions and liquid crystalline systems containing the anticholinesterase alkaloidal extract from Tabernaemontana divaricata. International Journal of Pharmaceutics, 2013. Applied formulation work aimed at transdermal delivery. Find on PubMed.
  7. Khongsombat O, Nakdook W, Ingkaninan K. Inhibitory effects of Tabernaemontana divaricata root extract on oxidative stress and neuronal loss induced by amyloid β(25-35) peptide in mice. Journal of Traditional and Complementary Medicine, 2018. A pretreatment design — see the cognitive sub-article for why that matters. Find on PubMed.
  8. Chanchal R, Balasubramaniam A, Navin R, Nadeem S. Tabernaemontana divaricata leaves extract exacerbate burying behavior in mice. Avicenna Journal of Phytomedicine, 2015. A small marble-burying study; read the results text, not just the title. Find on PubMed.

Back to Table of Contents

Key Research: Alkaloid Chemistry and Toxicity

  1. Naidoo CM, Naidoo Y, Dewir YH, Murthy HN, El-Hendawy S, Al-Suhaibani N. Major bioactive alkaloids and biological activities of Tabernaemontana species (Apocynaceae). Plants, 2021. The current genus-wide review; useful context, not species-specific proof. Find on PubMed.
  2. Bao MF, Yan JM, Cheng GG, et al. Cytotoxic indole alkaloids from Tabernaemontana divaricata. Journal of Natural Products, 2013. Conophylline’s sub-micromolar potency against five human cancer cell lines, isolated directly from this species. Find on PubMed.
  3. Dutta N, Pemmaraju DB, Ghosh S, et al. Alkaloid-rich fraction of Ervatamia coronaria sensitizes colorectal cancer through modulating AMPK and mTOR signalling pathways. Journal of Ethnopharmacology, 2022. Mouse tumour model, mechanism-level detail. Find on PubMed.
  4. Majumder C, Manna A, Halder S, et al. Indole-alkaloid-rich fraction of Ervatamia coronaria leaf extract regresses breast cancer by inducing apoptotic cell death. Biotechnology Reports, 2025. Reports little effect on normal cells — more careful than most of this literature on selectivity. Find on PubMed.
  5. Fujii M, Takei I, Umezawa K. Antidiabetic effect of orally administered conophylline-containing plant extract on streptozotocin-treated and Goto-Kakizaki rats. Biomedicine & Pharmacotherapy, 2009. Real oral efficacy data; conophylline sourced from Okinawan T. divaricata leaves. Find on PubMed.
  6. Kam TS, et al. Biologically active indole and bisindole alkaloids from Tabernaemontana divaricata. Organic & Biomolecular Chemistry, 2003. Confirms conophylline among the alkaloids isolated directly from this species. Find on PubMed.
  7. Poornima K, Chella Perumal P, Gopalakrishnan VK. Protective effect of ethanolic extract of Tabernaemontana divaricata against DEN and Fe-NTA induced liver necrosis in Wistar Albino rats. BioMed Research International, 2014. The hepatoprotective counter-finding to a purely cautionary reading. Find on PubMed.
  8. Alper K, Bajaj P, Kotbi N, et al. hERG blockade by iboga alkaloids. Cardiovascular Toxicology, 2016. The channel-level mechanism behind the cardiac caution — about the alkaloid class, not this species specifically. Find on PubMed.
  9. Meisner JA, Wilcox SR, Richards JB. Ibogaine-associated cardiac arrest and death: case report and review of the literature. Therapeutic Advances in Psychopharmacology, 2016. Documents the realised risk in the closest-related compound. Find on PubMed.
  10. Litjens RP, Brunt TM. How toxic is ibogaine? Clinical Toxicology, 2016. A sober review of the fatality and adverse-event literature for the alkaloid voacangine is one synthetic step from. Find on PubMed.

Back to Table of Contents

External Resources

Back to Table of Contents

Connections

Back to Table of Contents